Source : JAMA Network

Auteur : Stephan D. Fihn and al.


ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has propagated global shock waves that have disrupted nearly every aspect of human endeavor. Nowhere has this been more evident than in health care. Health care delivery systems in some locations have been overwhelmed, and even those not so severely affected have had to reorganize and restructure to concentrate resources to meet an anticipated surge of patients who are critically ill. In the absence of rapid and reliable testing, proven therapies, or even standard protocols for treatment, physicians and other clinicians have been forced to improvise, in some cases relying on the thinnest of evidence, to treat patients who are desperately ill.


Télécharger l’article complet


Source : Antiviral Research

Auteur : Mike Bray and al.


ABSTRACT

Caly et al. at Monash University in Australia recently published a paper in Antiviral Research, reporting that ivermectin, a medication widely used for the treatment of certain parasitic diseases in humans and livestock animals, inhibits the replication of SARS-CoV-2 in cell culture (Caly et al., 2020). Despite the authors’ cautious conclusion that ivermectin “warrants further investigation for possible benefits in humans,” the paper has excited widespread interest on medical and veterinary websites, which often incorrectly describe the drug as a treatment or cure for COVID-19. These inappropriate statements led to a warning by the US FDA, that ivermectin in veterinary products should not be used for human therapy,


Télécharger l’article complet


Source : Antiviral Research

Auteur : Leon Caly and al.


ABSTRACT

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.


Télécharger l’article complet


Source : ScienceDirect

Auteur : Renuka Choudhary and Anil K. Sharma


ABSTRACT

Alarming situation has been caused due to the emergence of COVID-19 infection around the world. There is an urgency of developing a therapeutic strategy in order to control the spread of COVID-19. Towards that initiative, potential drugs like hydroxychloroquine, ivermectin and azithromycin have been tested by diverse group of researchers worldwide for their potential against novel coronavirus. The present report presents together the comprehensive knowledge derived from the major researches about the above drugs altogether in context of the current health emergency around the world. Hydroxychloroquine and ivermectin were known to act by creating the acidic environment and inhibiting the importin (IMPα/β1) mediated viral import. Azithromycin was found to act similar to the hydroxychloroquine as an acidotropic lipophilic weak base. All the three categories of drugs seemed to potentially act against novel coronavirus infection. However, their efficacies need to be studied in detail individually and in combination in-vivo in order to combat COVID-19 infection.

Keywords: Coronavirus; Hydroxychloroquine; Ivermectin; Azithromycin


Télécharger l’article complet


Source : European Journal of Orthopaedic Surgery & Traumatology

Auteur : Cyril Maufrey et Alex Trompeter


“Un papier qui fait le tour des diverses activités redéployées par les orthopédistes dans le contexte covid” proposé par le Pr LIVERNEAUX Philippe.

Introduction:

We hope that you are staying safe during this COVID-19 pandemic that undoubtedly represents the biggest challenge humanity has faced in many generations. The global nature of the threat, the invisibility of the enemy and the unpredictable target have all contributed to creating the perfect storm hitting what we assumed was a robust equilibrium. Cynics say that perhaps, our planet will remain the only benefciary of this crisis through reduced pollution, a well-needed breath of fresh air for the disappearing fauna and fora.


Télécharger l’article complet


Source : ORCID

Auteur : Austin R. Morrison and al.


Letter to the Editor :

“Une « Letter to the Editor » concernant 2 patients avec forme  respiratoire sévère de Covid chez qui l’utilisation de Tocilizumab s’est accompagnée d’une Hypertriglycéridémie majeure. Donc surveillance métabolique rigoureuse à prévoir dans cette indication.” proposé par le Dr Laurent MEYER.

Abstract :

Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19.


Télécharger l’article complet


Source : Journal of International AIDS Society Auteur : Enver Akalin and al.

ANALYSE:

Commentateur : Dr David REY.

Objectif :

  • Résumé de l’efficacité clinique des ARV sur les virus SARS, MERS et SARS-CoV-2
Principaux résultats :
  • Pas de bénéfice dans les essais randomisés, les études observationnelles ne sont pas concluantes.
  • Based on available evidence it is uncertain whether LPV/r and other antiretrovirals improve clinical out- comes in severe symptomatic disease or prevent infection among patients at high risk of acquiring COVID-19.
Conclusion : 
  • Pas d’efficacité démontrée des ARV sur SARS, MERS et COVID-19
Accédez à l’analyse complète ICI.


Source : Pharmacological Research Auteur : Agostino Riva and al.

ANALYSE:

Commentateur : Dr David REY. Principaux résultats : 3 patients infectés VIH (2 hommes et 1 femme, 57 à 63 ans), font une infection COVID prouvée, alors qu’ils sont sous darunavir boosté tous les 3, avec un bon dosage plasmatique juste avant le COVID (donc une bonne observance). Tous les 3 étaient en charge virale indétectable. Traitement du COVID: darunavir maintenu dans 1 cas, passage au lopinavir dans les 2 autres, dans tous les cas avec hydroxychloroquine. Evolution favorable, mais 2 sont encore hospitalisés. Conclusion : Confirme l’absence d’efficacité du darunavir sur le SARS-CoV-2. Accédez à toute l’analyse ICI.


Source : The FEBS Journal Auteur : JL Olds et N Kabbani

ANALYSE

Commentateur : Dr David REY
  • Article publié avant l’étude parisienne suggérant un effet “protecteur” de la nicotine sur le risque COVID. Les auteurs rappellent ici la morbidité et la mortalité COVID augmentées chez les fumeurs actifs et anciens.  Discussion physiopathologique en rapport avec le récepteur commun nicotine – coronavirus ACE2.


Source : Chinese Journal of Integrative Médicine Auteur : LUO Hui and al.

ABSTRACT

Objective Since December 2019, an outbreak of corona virus disease 2019 (COVID-19) occurred in : Since December 2019, an outbreak of corona virus disease 2019 (COVID-19) occurred in Wuhan, and rapidly spread to almost all parts of China. This was followed by prevention programs recommending Wuhan, and rapidly spread to almost all parts of China. This was followed by prevention programs recommending Chinese medicine (CM) for the prevention. In order to provide evidence for CM recommendations, we reviewed Chinese medicine (CM) for the prevention. In order to provide evidence for CM recommendations, we reviewed ancient classics and human studies. ancient classics and human studies.

© Les Hôpitaux Universitaires de Strasbourg 2020 - Tous droits réservés